New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 12, 2012
07:02 EDTMDCO, BMYThe Medicines Co., Bristol-Myers sign global alliance pact for Recothrom
The Medicines Company (MDCO) and Bristol-Myers Squibb Company (BMY) announced that the companies have signed a global license and two year collaboration for Recothrom, a recombinant thrombin approved by the U.S. Food and Drug Administration for use as a topical hemostat to control non-arterial bleeding during surgical procedures. Recothrom net revenues in 2011 were $65M. The product is currently commercially available in the United States and Canada. The intellectual property license agreement is global and The Medicines Company anticipates pursuing approvals in additional countries. Under terms of the agreement, The Medicines Company will pay Bristol-Myers Squibb an upfront collaboration payment of $105M and an upfront option fee of $10M. The Medicines Company has also agreed to pay Bristol-Myers Squibb a tiered royalty on annual net revenues of Recothrom during the two-year collaboration term. Bristol-Myers Squibb will retain responsibility for the manufacturing of Recothrom and will be The Medicine Company's exclusive supplier of Recothrom during the term of the agreement. The option enables The Medicines Company to acquire the Recothrom assets for a purchase price based on average net sales during the two-year collaboration term. The transaction is expected to be accretive to EPS for The Medicines Company in 2013. The transaction is expected to be minimally accretive to EPS for Bristol-Myers Squibb in 2013 and 2014.
News For MDCO;BMY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 22, 2014
07:11 EDTMDCOMedicines Co. says Angiomax, Angiox revenue up 5% in first nine months
Subscribe for More Information
07:06 EDTMDCOThe Medicines Co. reports Q3 EPS (26c) , consensus (12c)
Subscribe for More Information
October 21, 2014
07:15 EDTBMYFDA to hold workshop on breast cancer drug development
Subscribe for More Information
October 20, 2014
09:48 EDTMDCOBrdiger Management reports 5.1% passive stake in The Medicines Co.
07:19 EDTBMYIBC Life Sciences to hold a conference
Subscribe for More Information
October 16, 2014
10:01 EDTBMYOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
08:42 EDTBMYBristol-Myers upgraded at BMO Capital
Subscribe for More Information
06:16 EDTBMYBristol-Myers upgraded to Outperform from Market Perform at BMO Capital
October 15, 2014
09:57 EDTBMYLeerink biotech analysts hold an analyst/industry conference call
Subscribe for More Information
October 14, 2014
11:23 EDTBMYBIND Therapeutics and The Conference Forum hold a conference
Subscribe for More Information
October 13, 2014
08:05 EDTBMYBristol-Myers, Pharmacyclics, Janssen announce clinical collaboration
Bristol-Myers Squibb Company (BMY), Pharmacyclics, Inc. (PCYC), and Janssen Research & Development, LLC (JNJ) announced today they have entered into a clinical trial collaboration agreement to evaluate the safety, tolerability and preliminary efficacy of Bristol-Myers Squibb’s investigational PD-1 immune checkpoint inhibitor OPDIVO in combination with IMBRUVICA, an oral Bruton's tyrosine kinase inhibitor co-developed and co-marketed by Pharmacyclics and Janssen. The Phase 1/2 study will focus on evaluating the safety and anti-tumor activity of combining OPDIVO and IMBRUVICA as a potential treatment option for patients with non-Hodgkin lymphoma, including diffuse large B-cell lymphoma, follicular lymphoma and chronic lymphocytic leukemia. Bristol-Myers Squibb has proposed the name OPDIVO, which if approved by health authorities, will serve as the trademark for the investigational drug, nivolumab. OPDIVO is part of a new class of cancer treatments known as immunotherapies, which are designed to harness the body’s own immune system in fighting cancer by targeting distinct regulatory components of the immune system. Each agent has individually shown activity against hematologic malignancies in clinical trials; pre-clinical evidence suggests OPDIVO and IMBRUVICA may have the potential for additive treatment effects in patients with hematologic malignancies. The study will be conducted by Janssen. Additional details of the collaboration were not disclosed.
07:25 EDTMDCOEuropean Association of Cardiothoracic Surgery to hold annual meeting
28th EACTS Annual Meeting is being held in Milan, Italy on October 11-15.
07:13 EDTBMYBioFlorida to hold a conference
Subscribe for More Information
October 10, 2014
10:03 EDTBMYBristol-Myers receives orphan status for melanoma treatment
Subscribe for More Information
08:19 EDTBMYMedivir announces Janssen initiates enrolment in phase II IMPACT study
Subscribe for More Information
07:14 EDTMDCOThe Medicines Co's Q3 Angiomax estimate lowered at Credit Suisse
Subscribe for More Information
October 9, 2014
16:57 EDTMDCOThe Medicines Co. announces journal publication of SOLO II phase 3 trial
The Medicines Company announced the publication of the results from the SOLO II phase 3 clinical trial of ORBACTIV, or oritavancin, for injection in the journal Clinical Infectious Diseases. ORBACTIV, is the first and only single dose intravenous antibiotic approved by FDA for the treatment of adults with Acute Bacterial Skin and Skin Structure Infections, or ABSSSI, caused or suspected to be caused by susceptible isolates of designated Gram-positive pathogens. The publication reported that a single, once only, 1200 mg intravenous dose of ORBACTIVTM was non-inferior to twice-daily intravenous dosing of vancomycin given for 7 to 10 days in patients with ABSSSI caused or suspected to be caused by Gram-positive bacteria, including methicillin-resistant Staphylococcus aureus. A single 1200 mg IV dose of ORBACTIV results in efficacy in ABSSSIs that is comparable and statistically non-inferior to vancomycin administered intravenously for 7-10 days. ORBACTIV had a safety profile comparable to vancomycin when monitored for up to 60 days following a single dose, with similar intensity, onset and duration of AEs.
October 8, 2014
08:03 EDTBMYBristol-Myers resolves outstanding U.S. litigation on efavirenz
Bristol-Myers Squibb Company says it has "successfully resolved all outstanding U.S. patent litigation relating to efavirenz, an active ingredient contained in our Sustiva -- efavirenz -- and Atripla products. Accordingly, we believe that loss of exclusivity in the U.S. for efavirenz should not occur until December 2017. Bristol-Myers Squibb remains committed to delivering our medicines and to developing new and innovative treatments to help patients prevail over serious disease. Atripla is currently the #1 prescribed U.S. regimen in its category, with over 8 million prescriptions written since its launch in 2006. Earlier this year the company submitted a new drug application to the U.S. Food and Drug Administration for a fixed-dose combination of atazanavir sulfate and cobicistat, an investigational pharmacokinetic enhancer. In addition, studies are ongoing for new treatments including an HIV-1 attachment inhibitor, an HIV-1 maturation inhibitor and an anti-PD-L1. The establishment of intellectual property rights allows Bristol-Myers Squibb to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. We will continue to defend our intellectual property rights against infringement as we remain focused on providing a deep and broad portfolio of innovative medicines to patients around the world."
07:18 EDTBMYInfectious Diseases Society of America to hold a conference
ID Week 2014 is being held in Philadelphia on October 8-12.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use